Healthcare
•1072 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (1072)
%
| Company | Market Cap | Price |
|---|---|---|
|
LAVA Therapeutics develops oncology therapies around its platform, placing it squarely in Biotech - Oncology.
|
$40.76M |
$1.55
+0.65%
|
|
Directly manufactures dental devices (Wand/STA) and related consumables for dental procedures.
|
$40.71M |
$0.52
-5.69%
|
|
The company directly markets and commercializes an ophthalmic bevacizumab product (ONS-5010/LYTENAVA) for retinal diseases, which is a clear ophthalmic drug product.
|
$40.28M |
$1.20
-2.44%
|
|
ctLNP/siRNA delivery platform enabling intracellular gene silencing in T cells for autoimmune indications (gene therapy modality).
|
$40.22M |
$5.72
-0.35%
|
|
BDMD manufactures microwave ablation systems and disposable MWA needles used for tumor ablation, which fits the Surgical Equipment product category.
|
$39.73M |
$1.58
-3.07%
|
|
Company focuses on discovery and development of oral small-molecule therapeutics powered by boron chemistry, with AN2-502998 for chronic Chagas disease and epetraborole for acute melioidosis, plus early oncology programs.
|
$39.23M |
$1.30
+2.36%
|
|
Lead programs are oral, small-molecule therapeutics (amezalpat and TPST-1495).
|
$38.30M |
$10.40
-2.07%
|
|
OTC Pain Relief & Analgesics private-label product line.
|
$37.68M |
$4.38
-8.68%
|
|
Core non-invasive neuromodulation devices (gammaCore, Quell, Sparrow Ascent, TAC-STIM) are the company's direct product offerings.
|
$37.10M |
$5.00
-5.12%
|
|
Dissolvable microneedle drug-delivery platform for skin cancer (Dermato-oncology) and the GnRH antagonist Teverelix for prostate cancer place Medicus Pharma squarely in oncology-focused biotechnology.
|
$37.07M |
$2.48
-3.13%
|
|
Preclinical oncology-focused biopharmaceutical company developing a high-affinity anti-CD47 antibody.
|
$36.68M |
$1.41
-9.03%
|
|
The company references proprietary diagnostic platforms and labeling/detection technologies used for molecular testing, aligning with diagnostic equipment.
|
$36.59M |
$0.70
|
|
IO Biotech operates in oncology-focused biotechnology and its lead products are cancer vaccines.
|
$36.37M |
$0.55
-4.81%
|
|
Elutia develops and sells implant-associated surgical envelopes (EluPro) used during operative procedures, a core surgical equipment product category.
|
$36.18M |
$0.89
+1.02%
|
|
Direct product briquilimab, a monoclonal antibody targeting the SCF/c-KIT axis for chronic urticaria, aligns with the Immunology Therapeutics category.
|
$36.05M |
$2.40
-3.23%
|
|
OT-101 is an RNA-targeted/antisense oncology therapeutic in late-stage clinical development.
|
$35.83M |
$0.09
-9.09%
|
|
Directly relates to cell therapy initiatives via cord blood stem cell sourcing and processing; CCEL's core business is cord blood banking and tissue storage, which aligns with cell therapy ecosystems.
|
$35.77M |
$4.43
+0.35%
|
|
Develops and sells in vitro diagnostic (IVD) kits for brain diseases using metabolomics and machine learning (diagnostic products).
|
$35.75M |
$2.02
|
|
Mural Oncology is focused on developing oncology immunotherapies and engineered cytokine therapeutics (nemvaleukin and related programs).
|
$35.75M |
$2.07
-0.48%
|
|
OnKure Therapeutics is a biotechnology company focused on oncology with a pipeline of targeted cancer therapies (lead PI3Kα mutant inhibitor).
|
$35.13M |
$2.60
+0.58%
|
|
Directly manufactures/provides a surgical robotic system (surgical equipment).
|
$34.64M |
$5.84
-10.43%
|
|
Diagnostic equipment capabilities as part of potential medical device manufacturing.
|
$34.55M |
$3.21
-3.60%
|
|
Direct placenta-derived cell therapy and MAIT-cell immunotherapy pipelines powering Pluri's core business.
|
$34.35M |
$4.39
-2.55%
|
|
Remote patient monitoring and ongoing health engagement across conditions.
|
$33.62M |
$15.30
-2.24%
|
|
Myomo's core product is the MyoPro myoelectric orthotic device, a prosthetics/implant category enabling upper-limb movement.
|
$33.50M |
$0.91
-12.50%
|
|
IGC-AD1 is the lead Alzheimer’s disease therapeutic candidate in Phase 2, directly mapped to Alzheimer’s Disease Therapeutics.
|
$33.48M |
$0.40
-4.29%
|
|
Rafael is focused on Trappsol Cyclo for Niemann-Pick Disease Type C1, a rare disease, making Rare Diseases a core investable theme.
|
$33.38M |
$1.34
-1.47%
|
|
POCI designs and manufactures customized components and subsystems for medical devices (micro-optics, assemblies).
|
$33.16M |
$4.33
|
|
IMG-007 is a monoclonal antibody targeting OX40 developed for immunology/inflammatory diseases, aligning with Immunology Therapeutics.
|
$32.01M |
$7.96
-2.21%
|
|
CEL-SCI develops oncology-focused immunotherapy products, with Multikine as the lead candidate for cancer treatment.
|
$31.77M |
$10.47
+2.25%
|
|
Product pipeline includes recombinant vaccine antigens (e.g., Mpox ferritin antigen) and vaccine-related proteins, tying to vaccines development/production.
|
$31.60M |
$1.05
-7.08%
|
|
Exicure's core biotechnology focus is on oncology, anchored by the GPCR USA lead asset (GPC-100.00).
|
$31.27M |
$4.95
-13.91%
|
|
Equipment-based health services may utilize diagnostic equipment for health screening and related activities.
|
$31.08M |
$0.08
|
|
Direct cardiology ablation devices (vCLAS system) used for VT treatment.
|
$31.07M |
$2.02
-14.04%
|
|
TENX's core program centers on levosimendan (TNX-103) for PH-HFpEF, a cardiovascular drug, aligning with the Cardiovascular Drugs tag.
|
$30.95M |
$7.46
-4.85%
|
|
Kezar's lead candidate zetomipzomib targets immune-mediated diseases (autoimmune hepatitis), aligning with Immunology Therapeutics.
|
$30.83M |
$4.22
-5.17%
|
|
In-house contract manufacturing capabilities via Cana Laboratories Cyprus (and DolCas) underpin higher-margin manufacturing revenue.
|
$30.76M |
$1.07
-8.15%
|
|
CID-103 is a fully human anti-CD38 monoclonal antibody developed for autoimmune diseases and organ transplant rejection, placing CASI in the Immunology Therapeutics space.
|
$30.28M |
$1.98
-3.41%
|
|
Acquisition of Bethesda Medical expands diagnostic imaging within BMGL's healthcare ecosystem.
|
$30.27M |
$1.64
+1.86%
|
|
SCYNEXIS is developing ibrexafungerp as an oral small-molecule antifungal; this directly aligns with the 'Oral Small Molecule Therapeutics' investable category.
|
$30.05M |
$0.77
-3.75%
|
|
ORLYNVAH is an oral small-molecule therapeutic antibiotic (sulopenem etzadroxil-probenecid).
|
$29.68M |
$0.74
-9.52%
|
|
Core product category consists of safety syringes with retraction technology, a primary revenue driver.
|
$29.18M |
$0.97
-7.17%
|
|
Lead assets (LTI-3.00, LTI-1.00) target Idiopathic Pulmonary Fibrosis and related rare pulmonary/fibrosis conditions with peptide-based therapeutics, placing Rein Therapeutics in the Biotech - Rare Diseases space.
|
$28.80M |
$1.30
-4.41%
|
|
Pathology Services / Laboratory testing is a core, directly-provided service offering.
|
$28.79M |
$19.04
-7.65%
|
|
Cadrenal's lead candidate tecarfarin is an oral small molecule anticoagulant, aligning with the Orals Small Molecule Therapeutics tag.
|
$27.59M |
$14.03
+0.14%
|
|
Boundless Bio operates as a biotech oncology company developing cancer therapies targeting ecDNA, fitting the Biotech - Oncology category.
|
$27.53M |
$1.23
-0.81%
|
|
Leap's core assets are antibody-based oncology therapies, placing it squarely in Biotech - Oncology.
|
$26.46M |
$0.64
-4.13%
|
|
Directly provides a proprietary drug-delivery platform (RaniPill GO/HC) for oral biologics.
|
$26.37M |
$0.46
-3.54%
|
|
PBFT02 is Passage Bio's lead gene therapy product, placing the company squarely in the Biotech - Gene Therapy category.
|
$26.32M |
$8.47
-5.57%
|
|
Allocetra is Enlivex's lead product, a macrophage-reprogramming cell therapy, directly fitting the 'Cell Therapy' category.
|
$25.29M |
$1.15
-1.71%
|
|
Ready-to-use pre-filled syringe candidates (Fedsyra and phenylephrine) form part of Talphera's drug delivery strategy.
|
$25.22M |
$1.23
-3.15%
|
|
Biotech cell therapy-oriented tissue regeneration using rhCollagen scaffolds.
|
$25.20M |
$2.20
-6.38%
|
|
Nortech focuses on complex electromedical devices and markets, aligning with Medical Devices & Biometrics.
|
$24.85M |
$9.00
-0.86%
|
|
PSTV directly develops radiopharmaceutical therapy using Rhenium-186 nanoliposomes (REYOBIQ) for CNS tumors.
|
$24.42M |
$0.72
-7.07%
|
|
Allarity's lead therapy stenoparib targets oncology indications (PARP/WNT inhibitor) representing its core Biotech - Oncology business.
|
$24.28M |
$1.61
-8.52%
|
|
Patented antiviral small-molecule therapeutics (MGX-0024) targeting respiratory illnesses.
|
$24.27M |
$2.20
-4.76%
|
|
The company’s core platforms are cell-based therapies (gamma delta T cells and cord blood-derived NK cells) used to treat cancer and autoimmune diseases.
|
$23.77M |
$2.06
-8.44%
|
|
Company focuses on oncology diagnostics and prognostics, fitting Biotech - Oncology.
|
$23.64M |
$1.47
+2.85%
|
|
Starco acquiring The Starco Group creates a direct Contract Manufacturing capability, aligning with Contract Manufacturing Organizations.
|
$23.53M |
$0.03
+0.83%
|
|
IB-Stim and RED represent neuromodulation-related medical devices, a core device category the company directly designs/manufactures.
|
$22.95M |
$3.18
-1.24%
|
|
Pharmacy equipment and some medical devices sold through healthcare operations qualify NXPL as a medical devices/biometrics-related distributor.
|
$22.64M |
$0.87
-0.51%
|
|
LuViva is a diagnostic equipment device used for cervical cancer screening and monitoring.
|
$22.48M |
$0.28
+16.67%
|
|
ProPhase Labs directly provides Laboratory Testing & Advisory Services via BE-Smart diagnostic testing.
|
$21.85M |
$0.53
+1.29%
|
|
Bee venom–based therapeutic for OA/MS pain aligns with Immunology Therapeutics.
|
$21.76M |
$1.88
+0.53%
|
|
Ketamir-2, MIRA-55, and SKNY-1 are all oral small-molecule therapeutics in the company's core pipeline.
|
$21.32M |
$1.26
-6.67%
|
|
Rallybio centers on rare-disease therapies (RLYB116 and RLYB332) and aligns its development strategy around treating rare conditions.
|
$21.26M |
$0.51
-7.11%
|
|
FibroBiologics' core business is fibroblast-based cell therapy with lead candidates CYWC628, CYMS101, and CybroCell, fitting the Biotech - Cell Therapy category.
|
$21.01M |
$0.55
-0.05%
|
|
HT-001 and HT-KIT are oncology-focused assets, placing Hoth Therapeutics squarely in Biotech - Oncology.
|
$20.87M |
$1.58
-5.39%
|
|
Directly produces ophthalmology device (SCS Microinjector) used for suprachoroidal injection delivery.
|
$20.62M |
$3.98
-8.72%
|
|
Lisata Therapeutics operates in oncology biotech with certepetide as its lead cancer therapy.
|
$20.38M |
$2.37
|
|
Company is a biotech focused on oncology therapeutic development.
|
$20.27M |
$18.43
|
|
EB06 (anti-CXCL10 monoclonal antibody) and EB05/EB07 (paridiprubart-host-directed therapeutics) and EB01 (daniluromer cream) are immunology/inflammatory disease therapeutics developed by Edesa, aligning with Immunology Therapeutics.
|
$20.23M |
$2.76
-4.17%
|
|
Offers Laboratory Testing & Advisory Services related to regulatory compliance and GLP data for decontamination validation.
|
$20.22M |
$1.01
+1.01%
|
|
Propanc Biopharma's core offering is a cancer therapy (PRP) in preclinical development, aligning with Biotech - Oncology.
|
$20.09M |
$1.73
-6.99%
|
|
NXGEL's revenue is driven by contract manufacturing, including their SilverSeal products and packaging capabilities.
|
$19.67M |
$2.57
-3.02%
|
|
Provides healthcare-related composite parts and healthcare product applications.
|
$19.56M |
$1.15
-3.36%
|
|
Company develops oncology-focused therapies (ENV-105, KROS candidates).
|
$19.55M |
$1.16
-12.12%
|
|
The lead program targeted a rare metabolic disease (PKU), aligning with the Rare Diseases investable theme.
|
$19.51M |
$1.67
-1.30%
|
|
DiversitAb is an antibody Discovery Platform used to generate fully human polyclonal antibodies; directly describes their core platform and product approach.
|
$19.14M |
$2.06
+4.04%
|
|
Envoy Medical's Acclaim Cochlear Implant and Esteem FI-AMEI are implanted prosthetic devices designed to treat hearing loss.
|
$18.87M |
$0.89
-8.29%
|
|
The company leverages contract manufacturing through 503B outsourcing facilities to produce its proprietary topical sildenafil cream and other products, fitting Contract Manufacturing Organizations as a core capability.
|
$18.76M |
$2.12
-4.93%
|
|
Mesh MEA organoid platform and preclinical monitoring systems function as diagnostic/lab instruments for research and testing.
|
$18.55M |
$0.42
-5.64%
|
|
Spryng is an orthopedic joint-therapy device used for osteoarthritis in dogs and horses.
|
$18.52M |
$1.28
+1.35%
|
|
Company designs and manufactures the Vivos Method dental oral appliances for obstructive sleep apnea, categorized under dental equipment.
|
$18.38M |
$3.12
+0.65%
|
|
Elite manufactures generic pharmaceutical products across CNS and other therapeutic areas (generic drugs).
|
$18.36M |
$0.63
+0.13%
|
|
X4's lead product mavorixafor is an oral small-molecule therapeutic for rare immunodeficiency conditions (WHIM CN).
|
$17.89M |
$3.09
-6.36%
|
|
IRIDEX directly manufactures and markets ophthalmology laser devices and related surgical ophthalmic equipment (e.g., MicroPulse, Endpoint Management, PASCAL/G6 systems).
|
$17.46M |
$1.04
-7.14%
|
|
ABPA and other respiratory conditions targeted by Pulmatrix's assets align with rare-disease/low-incidence biotech therapeutics.
|
$17.42M |
$4.77
+1.27%
|
|
Cuprina's MEDIFLY maggot debridement therapy and collagen/leech wound-care products are direct wound-care devices.
|
$17.28M |
$0.96
-12.73%
|
|
Directly manufactures and sells surgical hemostatic gauze used in human surgery (CelluSTAT).
|
$17.01M |
$0.07
-7.78%
|
|
Lead botanical drug Phyto-N targets inflammatory/immune-mediated diseases (ulcerative colitis, atopic dermatitis), aligning with Immunology Therapeutics.
|
$16.76M |
$0.70
-6.82%
|
|
Company's antiviral pipeline centers on small-molecule antivirals (ratutrelvir) targeting SARS-CoV-2.
|
$16.75M |
$3.01
-2.27%
|
|
Femasys develops and manufactures diagnostic equipment used for fallopian tube assessment and related gynecologic diagnostics (e.g., FemVue, FemCerv, FemChec, FemCath).
|
$16.68M |
$0.61
-8.12%
|
|
Core business is private-label contract manufacturing of vitamins, minerals, herbal and other health care products for global customers.
|
$16.44M |
$2.66
-3.28%
|
|
Direct focus on neuropsychiatric CNS therapeutics (roluperidone) for schizophrenia negative symptoms.
|
$16.43M |
$2.35
-2.89%
|
|
PMN is actively developing vaccine programs (PMN311 and PMN400), making Vaccines a direct product category for the company.
|
$16.28M |
$0.50
+4.64%
|
|
PV-10 is Provectus' lead oncology therapeutic developed from Rose Bengal Sodium (RBS).
|
$16.11M |
$0.08
+0.93%
|
|
Company's RF spectroscopy hardware and non-invasive diagnostic platform constitute a diagnostic equipment product line.
|
$16.05M |
$2.14
+3.88%
|
|
Emavusertib is an oncology asset, representing Curis's core product focus in cancer therapeutics.
|
$15.90M |
$1.52
-6.17%
|
|
AI Nose-derived odor detection capabilities are used as diagnostic equipment in health monitoring contexts.
|
$15.66M |
$3.77
-4.80%
|
Showing page 9 of 11 (1072 total stocks)
Loading industry metrics...
Loading comparison data...
